BioCentury
ARTICLE | Distillery Therapeutics

Neurology

February 11, 2019 9:19 PM UTC

Mouse studies identified a peptide agonist of MAS receptor that could help treat vascular dementia. The compound consists of the first six residues of angiotensin(1-7) - an endogenous peptide ligand of the MAS receptor - linked to a glycosylated and amidated serine to increase the peptide's serum half-life. In a mouse model of inflammation-induced vascular dementia, the compound decreased cognitive impairment and markers of brain inflammation compared with vehicle. Next steps by ProNeurogen Inc. include testing the peptide agonist in patients with vascular dementia, mixed dementia and traumatic brain injury.

MorphoSys AG and Tarix Orphan LLC have TXA127, a lanthionine-stabilized angiotensin(1-7) agonistic peptide, in Phase II testing for muscular dystrophy, Phase I testing for stem cell transplant and preclinical testing for blistering disorder and amyotrophic lateral sclerosis (ALS)...

BCIQ Company Profiles

University of Arizona

BCIQ Target Profiles

MAS receptor